Form 4: Ventyx Director's Options Cashed Out in Eli Lilly Merger
Merger-Related Insider Transaction
Ventyx Biosciences director Onaiza Cadoret-Manier's stock options were cancelled and converted to cash or no consideration following the acquisition by Eli Lilly and Company.
Summary
- Ventyx Biosciences, Inc. was acquired by Eli Lilly and Company through its wholly-owned subsidiary, RYLS Merger Corporation, with Ventyx surviving as a wholly-owned subsidiary of Eli Lilly.
- Director Onaiza Cadoret-Manier's stock options were affected by the merger, which became effective on March 4, 2026.
- Options with an exercise price less than or equal to the $14.00 Per Share Price were automatically cancelled and converted into a cash payment.
- Options with an exercise price greater than the $14.00 Per Share Price were automatically cancelled for no consideration.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a generally positive outcome for Ventyx shareholders and the reporting person, as the company was acquired and in-the-money options were cashed out, reflecting a successful exit for the independent entity.
Positives
- Director Onaiza Cadoret-Manier received cash for her 'in-the-money' stock options, totaling approximately $1,064,195.
- The merger indicates a successful acquisition for Ventyx Biosciences shareholders, as the Per Share Price was $14.00.
Negatives
- Director Onaiza Cadoret-Manier's 'out-of-the-money' stock options, totaling 36,364 shares (15,937 + 20,427), were cancelled for no consideration.
- Ventyx Biosciences, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Eli Lilly and Company.
Future Outlook
The filing does not contain forward-looking statements or guidance for Ventyx Biosciences as an independent entity, as it has become a wholly-owned subsidiary of Eli Lilly and Company.
Industry Context
StockSavvy.ai notes that the acquisition of Ventyx Biosciences by Eli Lilly and Company reflects a broader trend of consolidation in the biopharmaceutical sector, where larger pharmaceutical companies acquire smaller biotech firms to bolster their pipelines and gain access to innovative therapies. This specific transaction highlights the value placed on Ventyx's assets, leading to a $14.00 per share acquisition price.
Comparison to Industry Standards
- The acquisition price of $14.00 per share for Ventyx Biosciences can be compared to recent biotech acquisitions, such as Pfizer's acquisition of Seagen for $43 billion ($229 per share) or Merck's acquisition of Prometheus Biosciences for $10.8 billion ($200 per share). While the per-share price differs significantly due to company size and stage, the underlying principle of acquiring promising assets remains consistent.
- The treatment of stock options, where in-the-money options are cashed out and out-of-the-money options are cancelled for no consideration, is standard practice in M&A transactions, aligning with global benchmarks for corporate takeovers.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Onaiza Cadoret-Manier | N/A (Ventyx is now a subsidiary) | March 4, 2026 | Ventyx Biosciences became a wholly-owned subsidiary of Eli Lilly and Company following a merger, which typically results in changes to the board structure of the acquired entity. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Company Status | Ventyx Biosciences, Inc. ceased to be an independent publicly traded company and became a wholly-owned subsidiary of Eli Lilly and Company. | March 4, 2026 | This fundamentally alters Ventyx's corporate governance structure, integrating it into Eli Lilly's framework and eliminating its independent public board and shareholder base. |
Stakeholder Impact
- Shareholders of Ventyx Biosciences received $14.00 per share in cash as part of the merger consideration.
- Employees of Ventyx Biosciences are now part of Eli Lilly and Company, subject to Eli Lilly's corporate policies and structure.
- Directors like Onaiza Cadoret-Manier had their stock options converted to cash or cancelled based on the merger terms.
Key Dates
| Date | Description |
|---|---|
| January 7, 2026 | Date of the Agreement and Plan of Merger between Ventyx Biosciences, Eli Lilly and Company, and RYLS Merger Corporation. |
| March 4, 2026 | Date of earliest transaction reported, corresponding to the effective time of the merger and option cancellation. |
| January 11, 2033 | Expiration date of a cancelled out-of-the-money stock option. |
| June 15, 2033 | Expiration date of a cancelled out-of-the-money stock option. |
| January 21, 2034 | Expiration date of a cancelled in-the-money stock option. |
| June 6, 2034 | Expiration date of a cancelled in-the-money stock option. |
| June 5, 2035 | Expiration date of a cancelled in-the-money stock option. |
Keywords
Ventyx Biosciences, Eli Lilly, Merger, Acquisition, Stock Options, Form 4, Insider Transaction, Corporate Governance, VTYX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.